{Title}

NewsMakers | 2019

26th Annual NewsMakers in the Biotech Industry



September 6, 2019 | New York City


NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to take their story to Wall Street each Fall. Thus, NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

Last year, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than $600 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion dedicated to biotech.

NM 2018 Attendees


Return to Conferences List
SCHEDULE
Friday, September 6, 2019

7:30 AM  to  8:50 AM
Registration & Continental Breakfast
4th Floor Reception Area
Hosted by WBB Securities LLC
8:50 AM  to  9:00 AM
Welcome & Introductions
Room - 402 / 403
Welcome & Introductions
Room - 404/405

9:00 AM  to  9:20 AM
Brooklyn ImmunoTherapeutics LLC
Room - 402 / 403
Cytokine-based therapy to treat cancer

Breakout Room - 401 (9:20 AM - 9:50 AM)
BioXcel Therapeutics Inc. (NASDAQ:BTAI)
Room - 404/405
Using AI to identify new indications for existing products

WEBCAST

Breakout Room - 406 (9:20 AM - 9:50 AM)

9:20 AM  to  9:40 AM
Landos Biopharma Inc.
Room - 402 / 403
Oral therapeutics for autoimmune disease

Breakout Room - 408 (9:40 AM - 10:10 AM)
AB Science S.A. (Euronext:AB)
Room - 404/405
Late-stage tyrosine kinase inhibitor for oncology, CNS disorders and inflammatory disease

WEBCAST

Breakout Room - 409 (9:40 AM - 10:10 AM)

9:40 AM  to  10:00 AM
Refuge Biotechnologies Inc.
Room - 402 / 403
Genetic engineering of immune cells

Breakout Room - 401 (10:00 AM - 10:30 AM)
Hookipa Pharma Inc. (NASDAQ:HOOK)
Room - 404/405
Arenavirus platform to treat infectious disease and cancer

10:00 AM  to  10:20 AM
Senti Biosciences Inc.
Room - 402 / 403
Engineered biological circuits to generate adaptive cell and gene therapies

Breakout Room - 408 (10:20 AM - 10:50 AM)
ChemoCentryx Inc. (NASDAQ:CCXI)
Room - 404/405
Complement C5a receptor and chemokine receptor inhibitors

WEBCAST AUDIO

Breakout Room - 409 (10:20 AM - 10:50 AM)

10:20 AM  to  10:40 AM
Aro Biotherapeutics Co.
Room - 402 / 403
Centyrin platform for multi-target delivery

Breakout Room - 401 (10:40 AM - 11:10 AM)
Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877; NEEQ:833330)
Room - 404/405
Immuno-oncology pipeline includes mAbs against PD-1 and BTLA

WEBCAST

Breakout Room - 406 (10:40 AM - 11:10 AM)

10:40 AM  to  11:00 AM
Bridge Biotherapeutics Inc.
Room - 402 / 403
Virtual Korean biotech with therapies for UC and IPF

Breakout Room - 408 (11:00 AM - 11:30 AM)
Sorrento Therapeutics Inc. (NASDAQ:SRNE)
Room - 404/405
Pipeline includes cell therapies and antibodies to treat cancer as well as pain management programs

Breakout Room - 409 (11:00 AM - 11:30 AM)

11:00 AM  to  11:20 AM
Nordic Nanovector ASA (OSE:NANO)
Room - 402 / 403
Antibody-radionuclide-conjugates to treat hematological cancers

Breakout Room - 401 (11:20 AM - 11:50 AM)
Casma Therapeutics Inc.
Room - 404/405
Evaluating the entire autophagy pathway for a broad swath of diseases

Breakout Room - 406 (11:20 AM - 11:50 AM)

11:00 AM  to  11:59 AM
Panel Session
Room - 411
Staying Ahead of the Risk Curve – Has Wall Street Seen All of This Before?
Life science portfolios all face technology risk, regulatory risk, reimbursement risk, political risk, financial risk and management risk. But if today’s headlines are changing, have portfolio managers actually been forced to recalculate how they manage risk?

• Session Chair: David Flores, CEO, BioCentury

Panelists -
• Reni J. Benjamin, Ph.D., Managing Director, Biotechnology Equity Research, JMP Securities LLC
• Rakhee Bhagat, Director of Equity Capital Markets, William Blair & Co.
• Rhett Brown, Managing Director, Lazard Asset Management
• Anders Hove, M.D., Partner, Acorn Bioventures
11:20 AM  to  11:40 AM
Incysus Therapeutics Inc.
Room - 402 / 403
Allogeneic therapies to treat cancer, with a focus on solid tumors

Breakout Room - 408 (11:40 AM - 12:10 PM)
11:40 AM  to  12:00 PM
EpimAb Biotherapeutics Inc.
Room - 402 / 403
Bi-specific antibody platform for immuno-oncology

Breakout Room - 402/403 (12:00 PM - 12:30 PM)
12:00 PM  to  1:30 PM
Lunch with the Companies
8th Floor
1:30 PM  to  1:50 PM
TCR2 Therapeutics Inc. (NASDAQ:TCRR)
Room - 404/405
Developing T cell receptor fusion constructs (TRuCs) to treat solid tumors

WEBCAST

Breakout Room - 401 (1:50 PM - 2:20 PM)
1:30 PM  to  2:29 PM
Panel Session
Room - 411
Is the Deluge of New Technology Really Changing Risk?
Investors are balancing the upside of once-and-done cell and gene therapies with the risk of complex manufacturing, new infrastructure and unwritten regulatory rules. But has the inherent risk of new biology changed that much, and what are the lessons from the rise of first-generation biologics?

• Session Chair: Simone Fishburn, Ph.D., Vice President and Editor-in-Chief, BioCentury

Panelists -
• Jun Bao, Ph.D., President & CEO, Impact Therapeutics Inc.
• Susan Dillon, Ph.D., co-founder, President & CEO, Aro Biotherapeutics Co.
• Tim Lu, M.D., Ph.D., co-founder & CEO, Senti Biosciences Inc.
• Igor Matushansky, M.D., Ph.D., CMO & Global Head of R&D, Hookipa Pharma Inc.
1:50 PM  to  2:10 PM
Aldeyra Therapeutics Inc. (NASDAQ:ALDX)
Room - 404/405
Immune-mediated pipeline focused on ocular and systemic diseases

Breakout Room - 408 (2:10 PM - 2:40 PM)
2:10 PM  to  2:30 PM
Rockwell Medical Inc. (NASDAQ:RMTI)
Room - 404/405
Markets water soluble iron drug for CKD patients

WEBCAST

Breakout Room - 401 (2:30 PM - 3:00 PM)
2:30 PM  to  2:50 PM
Velicept Therapeutics Inc.
Room - 402 / 403
Compounds to treat OAB and IBS

Breakout Room - 408 (2:50 PM - 3:20 PM)
Impact Therapeutics Inc.
Room - 404/405
Pipeline includes PARP-1 inhibitor to treat solid tumors

Breakout Room - 409 (2:50 PM - 3:20 PM)

2:50 PM  to  3:10 PM
Kymera Therapeutics Inc.
Room - 402 / 403
Protein degradation for oncology, autoimmunity

Breakout Room - 402/403 (3:10 PM - 3:40 PM)
PRESENTERS

Presenting Companies are hand-picked by BioCentury based on rigorous selection criteria, including investor validation, upcoming milestones, unpartnered assets and innovative science, informed by the collective intelligence of the NewsMakers Sponsors. For information on becoming a Presenting Company, please email Eric Pierce.

  • AB Science S.A.
  • Aldeyra Therapeutics Inc.
  • Aro Biotherapeutics Co.
  • BioXcel Therapeutics Inc.
  • Bridge Biotherapeutics Inc.
  • Brooklyn ImmunoTherapeutics LLC
  • Casma Therapeutics Inc.
  • ChemoCentryx Inc.
  • EpimAb Biotherapeutics Inc.
  • Hookipa Pharma Inc.
  • Impact Therapeutics Inc.
  • Incysus Therapeutics Inc.
  • Kymera Therapeutics Inc.
  • Landos Biopharma
  • Myovant Sciences GmbH
  • Nordic Nanovector ASA
  • Refuge Biotechnologies Inc.
  • Rockwell Medical
  • Senti Biosciences Inc.
  • Shanghai Junshi Biosciences Co. Ltd.
  • Sorrento Therapeutics Inc.
  • TCR2 Therapeutics Inc.
  • Velicept Therapeutics Inc.
SPONSORS

BioCentury pioneered the "turf-neutral" concept on Wall Street, creating an open door for all members of the financial community to do business with independently selected Presenting Companies.

This approach has been possible because of the durable support of our Sponsors, whose endorsements enable BioCentury to make this truly "A Collaborative Gathering of the Corporate and Investment Communities."

For information on becoming a sponsor, please email Eric Pierce.

SPONSORS

  • {title}
  • {title}